{"created":"2023-05-15T09:06:17.905239+00:00","id":12938,"links":{},"metadata":{"_buckets":{"deposit":"8045b27d-9df2-4d69-967c-62f82860e06f"},"_deposit":{"created_by":14,"id":"12938","owners":[14],"pid":{"revision_id":0,"type":"depid","value":"12938"},"status":"published"},"_oai":{"id":"oai:sapmed.repo.nii.ac.jp:00012938","sets":["1875:1978:1986"]},"author_link":["19169","19170","19171"],"item_2_alternative_title_18":{"attribute_name":"その他のタイトル","attribute_value_mlt":[{"subitem_alternative_title":"The treatment strategy with a monoclonal antibody against HER2-positive breast cancer"}]},"item_2_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2012-10-31","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"1","bibliographicPageEnd":"33","bibliographicPageStart":"29","bibliographicVolumeNumber":"72","bibliographic_titles":[{"bibliographic_title":"市立札幌病院医誌 = Acta medica nosocomi Sapporo = The Journal of Sapporo City General Hospital"}]}]},"item_2_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"分子標的薬の出現により乳癌治療は大きな変化を遂げつつある。2012年現在、保険診療で投与可能な分子標的薬はトラスツズマブ、ラパチニブ、ベバシズマブの3種である。最も多く投与されているトラスツズマブは転移再発例予後を大きく改善させた。当院乳癌転移再発62例中HER2陽性17例で初診時転移例7例、HER2陰性では38例中9例とHER2陽性で病期進行例が多かった。予後はHER2陽性で17例中原癌死5例、陰性で38例中9例とほぼ同等、初診時転移例のみではHER2陽性7例中原癌死1例、生存6例(86％)、陰性9例中原癌死2例、生存6例(67％)とHER2陽性でより長期生存が期待できた。2008年には術後投与に保険適応拡大され、更なる予後改善に貢献している。","subitem_description_type":"Abstract"}]},"item_2_publisher_32":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"市立札幌病院"}]},"item_2_source_id_7":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"0288-6073","subitem_source_identifier_type":"ISSN"}]},"item_2_version_type_15":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"大川, 由美"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"上坂, 貴洋"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"西澤, 竜矢"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2018-07-21"}],"displaytype":"detail","filename":"l425672129.pdf","filesize":[{"value":"906.6 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"l425672129.pdf","url":"https://sapmed.repo.nii.ac.jp/record/12938/files/l425672129.pdf"},"version_id":"35e1580f-0a78-4e12-bf6d-46cfaf6c15ae"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"乳癌","subitem_subject_language":"ja","subitem_subject_scheme":"Other"},{"subitem_subject":"HER2","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"抗分子標的薬","subitem_subject_language":"ja","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"乳癌における分子標的薬治療（特集分子標的薬を用いた治療戦略）","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"乳癌における分子標的薬治療（特集分子標的薬を用いた治療戦略）","subitem_title_language":"ja"}]},"item_type_id":"2","owner":"14","path":["1986"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2014-05-15"},"publish_date":"2014-05-15","publish_status":"0","recid":"12938","relation_version_is_last":true,"title":["乳癌における分子標的薬治療（特集分子標的薬を用いた治療戦略）"],"weko_creator_id":"14","weko_shared_id":-1},"updated":"2023-12-13T04:30:17.331786+00:00"}